Potential use of ellagic acid for endometriosis treatment: its effect on a human endometrial cell cycle, adhesion and migration by Mc Cormack, Bárbara Andrea et al.
rsc.li/food-function
Food &
Function
Linking the chemistry and physics of food with health and nutrition
rsc.li/food-function
ISSN 2042-650X
PAPER
Xian Wu, Hang Xiao et al. 
A metabolite of nobiletin,  4' -demethylnobiletin and 
atorvastatin synergistically inhibits human colon cancer cell 
growth by inducing G0/G1 cell cycle arrest and apoptosis 
Volume 9
Number 1
January 2018
Pages 1-658Food &
Function
Linking the chemistry and physics of food with health and nutrition
This is an Accepted Manuscript, which has been through the  
Royal Society of Chemistry peer review process and has been 
accepted for publication.
Accepted Manuscripts are published online shortly after acceptance, 
before technical editing, formatting and proof reading. Using this free 
service, authors can make their results available to the community, in 
citable form, before we publish the edited article. We will replace this 
Accepted Manuscript with the edited and formatted Advance Article as 
soon as it is available.
You can find more information about Accepted Manuscripts in the 
Information for Authors.
Please note that technical editing may introduce minor changes to the 
text and/or graphics, which may alter content. The journal’s standard 
Terms & Conditions and the Ethical guidelines still apply. In no event 
shall the Royal Society of Chemistry be held responsible for any errors 
or omissions in this Accepted Manuscript or any consequences arising 
from the use of any information it contains. 
Accepted Manuscript
View Article Online
View Journal
This article can be cited before page numbers have been issued, to do this please use:  B. Mc Cormack,
M. Bilotas, D. Madanes, A. Ricci, J. J. Singla and I. Barañao, Food Funct., 2020, DOI:
10.1039/D0FO00267D.
11 Ellagic Acid potential use for endometriosis treatment: its effect on human endometrial cell 
2 cycle, adhesion and migration.
3
4 Short title: Ellagic acid possible endometriosis treatment.
5
6 B.A. Mc Cormack1, M.A. Bilotas1, D. Madanes1, A.G. Ricci1, J.J Singla2 and R.I. Barañao1.
7
8 1Laboratorio de Inmunología de la Reproducción, Instituto de Biología y Medicina Experimental, 
9 (IBYME-CONICET), Vuelta de Obligado 2490, Buenos Aires C1428ADN, Argentina
10 2Hospital de Clínicas “José de San Martín”, Av. Córdoba 2351, Buenos Aires C1120AAR, 
11 Argentina
12
13 Correspondence: Bárbara A. Mc Cormack. Vuelta de Obligado 2490, Buenos Aires C1428ADN, 
14 Argentina. Phone number: 011 4783-2869 E-mail: barbymccormack@gmail.com
Page 1 of 26 Food & Function
Fo
od
&
Fu
nc
tio
n
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
22
 A
pr
il 
20
20
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f N
ew
 E
ng
la
nd
 o
n 
4/
22
/2
02
0 
2:
35
:4
2 
PM
. 
View Article Online
DOI: 10.1039/D0FO00267D
215 Abstract 
16 Endometriosis is a common and challenging condition of reproductive-aged women that is defined 
17 as the presence of endometrial-like tissue outside the uterine cavity. Despite its prevalence, there is 
18 still no effective therapeutics so we aim to evaluate the ellagic acid (EA) effect on the most relevant 
19 aspects that are known to be altered in endometriosis. Endometrial primary cultures from women 
20 with and without endometriosis and endometrial cell lines were incubated with EA (50 and 100µM) 
21 for 24 and 48 h. The results demonstrated that EA arrest endometrial stromal cell cycle on G2 / M 
22 phase, after 48 h. In addition, EA 100μM treatment significantly decreased ECC-1 cell migration at 
23 20 h and T-HESC cell migration at 10 h and 20 h; while EA 50μM caused a significant decreased 
24 on T-HESC cell migration at 20 h. On the other hand, we proved that treatment with EA for 24 h 
25 reduces T-HESC and ECC-1 adhesion to plastic. However, we did not find an effect of EA on cell 
26 proliferation. EA has an inhibitory effect on endometrial cell adhesion, migration and cell cycle 
27 progression in vitro. These highlight the idea to investigate natural compounds as a novel and 
28 promising therapeutic treatment for endometriosis.
29
30 Keywords: endometriosis - Ellagic Acid - migration - adhesion - cell cycle
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331 1. Introduction 
32 Endometriosis is one of the most common benign gynecological diseases in women of 
33 reproductive age and is defined by the presence of endometrial-like tissue (epithelial and stromal 
34 elements) outside the uterine cavity1. It affects approximately 10% of the female population causing 
35 severe pelvic pain and infertility in 30-50% of the patients who suffer it. This is a disease with a 
36 complex etiology and the most accepted theory for endometriosis development is Sampson`s 
37 implantation theory based on retrograde menstruation2. According to this theory, for the 
38 endometriotic lesions establishment and maintenance, it is necessary that the endometrial cells 
39 reach the peritoneal cavity, adhere to the peritoneum, invade it, vascularize it and have the capacity 
40 to proliferate, therefore the migration, adhesion, and proliferation are crucial processes in 
41 endometriosis development. In addition, endometriosis is underdiagnosed because a large 
42 proportion of affected women are asymptomatic or their strong pelvic pain cannot be considered as 
43 specific symptoms of a disease. In general, the first doctor’s visit are due to difficulty conceiving 
44 and, at present, laparoscopy is the only diagnostic method, which causes long delays before women 
45 acquire a definitive diagnosis 3.
46 Current treatments for endometriosis involve the surgical removal of implants and/or the 
47 induction of an hypoestrogenic state using combined oral contraceptives, progestagens alone or 
48 GnRH analogues, because it is an estrogen-dependent disease. That’s why current medical therapies 
49 for endometriosis do not allow conception in women under treatment 4. In addition, these therapies 
50 are not completely effective and have several adverse side effects leading to high recurrence rates 5,6 
51 and avoiding their long term use 7–9.
52 The search for novel treatments for endometriosis, more accessible, with no side effects and that 
53 allow pregnancy, guided us to evaluate natural compounds. The consumption of berries and other 
54 polyphenol-enriched foods or juices has been associated with positive health effects like antioxidant 
55 properties, prevention of cardiovascular diseases and cancer 10,11. Ellagitannins (ETs) and EA are 
56 polyphenols12 present in those fruits, nuts and seeds13–15. Taking into account the diverse effects that 
57 the EA exerts on different cell types16–20, we think that this natural compound could be a good 
58 option as an alternative therapy for endometriosis. In addition to the known anti-inflammatory, 
59 antiglycolytic, antioxidant and antimicrobial effects of its metabolites21, it has been described that 
60 the EA has an antiproliferative and proapoptotic effect on colon, breast, and prostate22 cancer cell 
61 lines. It also inhibits cell migration and the production of pro-matrix-metalloproteases 2 and 9 and 
62 gelatin. It has anti-angiogenic action since it decreases the levels of vascular endothelial growth 
63 factor 165. (VEGF 165)23,24.
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464 In addition, considering that endometriosis is an estrogen-dependent pathology, another factor 
65 that led us to evaluate this compound as a possible treatment for endometriosis is the fact that it has 
66 been described that one of the metabolites of EA, urolithin B is an antagonist of the aromatase 25, 
67 and this antiestrogenic activity of EA has been proven by other authors26,27.
68 However, EA has not been tested as a therapeutic alternative for endometriosis. 
69 The aim of this work was to assess the effect of EA on proliferation, cell cycle progression, 
70 adhesion and migration in human endometrial cells in an in vitro model of endometriosis. 
71
72 2. Experimental methods 
73 2.1. Patients
74 In this study participated women on reproductive age who underwent diagnostic laparoscopies due 
75 to infertility, tubal obstruction or other pathology, and who had not received treatment during the 
76 last six months. They were classified into two groups: a) Patients with endometriosis diagnosed by 
77 laparoscopy and confirmed by histological studies (the stages I, II, III, and IV were determined 
78 according to the Revised American Society for Reproductive Medicine Classification28) and b) 
79 Control women who did not suffer endometriosis or other pathology that could alter the cell 
80 population to be evaluated.
81 After written consent from the patients, endometrial biopsies were taken during the laparoscopy 
82 with diagnostic and therapeutic purposes, yielding to our group a small fraction of the material. 
83 Biopsies of eutopic endometrium were obtained from all subjects as described previously 29,30. 
84 Patient characteristics are provided in Table 1.
85 This study was approved by the Ethics and Research Committee of the Instituto de Biología y 
86 Medicina Experimental - Consejo Nacional de Investigaciones Científicas y Técnicas (IBYME-
87 CONICET) of  Buenos Aires, Argentina, on 26 May 2015 (reference CE 005 - April/2015). Office 
88 of Laboratory Animal Welfare (OLAW) Assurance indentification number: F16-00065 (A5072-01). 
89
90 2.2. Isolation and culture of endometrial stromal and epithelial cells
91 We obtained epithelial and stromal cells from eutopic endometrial biopsies. The cells were 
92 enzymatically separated and isolated by successive centrifugations, and primary cultures were 
93 established for in vitro studies. Briefly, tissue was minced, washed and placed in Dulbecco's 
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594 Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12, Gibco) supplemented with 
95 antibiotic-antimycotic (penicillin 100 IU/ml, streptomycin 100 mg/ml and amphotericin B 25 
96 mg/ml, Gibco) and collagenase 0.5 mg/ml (type I, Gibco). After 2 h of incubation at 37°C in a 5% 
97 CO2 atmosphere, the resulting suspension was centrifuged at 100 x g for 5 minutes, and the pellet 
98 and supernatant were separated and reserved. The pellet containing epithelial glands was 
99 resuspended in culture medium and spun again at 100 x g for 5 minutes, so the final pellet mainly 
100 contained epithelial cells. This enriched epithelial fraction was cultured with MEM D-Val 
101 supplemented with 10% fetal bovine serum (FBS) (Gibco) and grown to sub-confluence (70–80%) 
102 at 37°C before the experiments. On the other hand, the supernatant containing mainly stromal cells 
103 was centrifuged at 400 x g for five minutes and the pellet containing mainly stromal cells were 
104 resuspended and the cells counted and plated with DMEM/F12 supplemented with 10% FBS and 
105 antibiotic-antimycotic to grow up to sub-confluence (70–80%) in a humidified environment with 
106 5% CO2 at 37°C. It has been previously shown that this method guarantees a high purity of each 
107 type of cells in culture 31. 
108
109 2.3. Cell line and culture conditions
110 T-HESC (ATCC® CRL4003™) was derived from the stromal cells obtained from an adult woman 
111 with myomas32. The primary stromal endometrium cells were immortalized by infection with 
112 supernatant from the packaging cell line pA317-hTERT (Geron Corp.; Menlo Park, CA), which 
113 expressed the hTERT and the puromycin resistance genes. They were cultured in DMEM/F-12 
114 supplemented with 10% FBS (PAA Laboratories, USA) in a phosphate buffered saline (PBS) 
115 modified environment with 5% CO2 at 37°C.
116 ECC-1 (ATCC® CRL2923™) was derived from endometrial epithelial cells from a human 
117 adenocarcinoma33. The cultures were maintained with Roswell Park Memorial Institute (RPMI)- 
118 1640 med supplemented with 10% fetal bovine serum, 1% pyruvate at 37°C in the presence of 5% 
119 CO2. 
120
121 2.4. Cell proliferation assay
122 For cell proliferation assays, 5x103 ECC-1 cells/well, 5x103 T-HESC cells/well, 5x104 primary 
123 endometrial epithelial cells/well or 2x104 primary endometrial stromal cells/well from eutopic 
124 tissue of women with endometriosis and controls were plated in 96 well culture plates with their 
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6125 corresponding media culture supplemented with 10 % FBS and incubated at 37°C in a 5% CO2 
126 atmosphere. When cells reached a 70% confluence, cultures were washed with PBS and incubated 
127 for 24 or 48 h with 50 µM and 100 µM EA in fresh medium supplemented with 1% fetal bovine 
128 serum. Basal conditions were obtained by incubating cells with the vehicle used to dissolve the EA: 
129 1% sodium hydroxide (NaOH, Sigma-Aldrich). We based on previous in vitro studies to fix the 
130 effective dose of EA; hence we arrived at these concentrations22,34–39. Each treatment condition was 
131 carried out in quadruplicate. Cell proliferation was determined by a colorimetric assay using the 
132 WST-1 Cell Proliferation Kit according to the manufacturer instructions (Roche Applied Science). 
133 Absorbance was measured at 450 nm using a multi-well plate reader. Cell proliferation was 
134 expressed as percentage of basal conditions in each experiment. 
135
136 2.5. Cell Cycle Analysis   
137 For cell cycle analysis, 2.5 x 105 T-HESC and ECC-1 cells/well were plated in 6 well culture plates 
138 with their corresponding culture medium supplemented with 10% fetal bovine serum. After 24 h, 
139 cultures were washed and incubated with different concentrations of EA (50 and 100 µM) in 
140 medium supplemented with 1% FBS for 24 or 48 h. Then, cells were harvested using 0.25% trypsin 
141 (Gibco) and centrifuged at 300 x g for 5 minutes. The supernatants were removed; cells were 
142 washed with ice-cold PBS, and fixed by slowly adding ice-cold 70% ethanol while mixing the 
143 solution in a vortex at low speed. Cells were kept at -20°C until assayed. On the day of the assay, 
144 tubes containing cells were centrifuged at 100 x g for 5 minutes and the supernatants were removed. 
145 Pellets were carefully resuspended adding the DNA-staining solution (50 µg/ml propidium iodide 
146 (Sigma-Aldrich) in PBS) and kept in the dark for 15 minutes at room temperature. Finally, cell 
147 cycle distribution was determined using a flow cytometer (FACS Canto II, BD Biosciences). The 
148 results were analyzed using Cyflogic 1.2.1 software. All treatments were compared to the basal 
149 condition.  
150
151 2.6. Scratch (wound healing) assay
152 The wound healing assay was carried out using an established procedure 40. Cells were seeded in a 6 
153 well plate and allowed to adhere for 48 h. Then the monolayer was wounded by cross scratching 
154 with a 200 μl pipette tip. The detached cells were removed by rinsing with PBS. Immediately after 
155 wounding, 50 or 100 μM EA was added in culture media supplemented with 1% FBS. Images of 
156 the scratch were acquired immediately after wounding (0 h) and 5, 10 and 20 h later. All treatments 
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7157 were compared to the basal condition. The healing rate was calculated using the closure ratio 
158 analysis method 41: 
159 Healing rate (%) = [(0 h scratch area - X h scratch area)/0 h scratch area] × 100. 
160
161 2.7. Adhesion assay to plastic.
162 Cell adhesion to plastic was evaluated in ECC-1 and T-HESC cultures treated with EA. Briefly, 
163 cells were cultured in their respective culture medium supplemented with 10% fetal bovine serum, 
164 at 37° with 5% CO2 until reach a 70% confluence. Then, the cells were treated for additional 24 h 
165 with vehicle or 50-100 μM EA in culture medium supplemented with 1% fetal bovine serum. 
166 Following, the cells were harvested with trypsin 0.25% (Gibco), resuspended in serum-free medium 
167 and leave to recover for 40 minutes. Following recovering, cell suspension was added to 6 well 
168 culture plates (104 cells/ml/well) and cultured in a 5% CO2 atmosphere at 37°C for 60 minutes. 
169 After that, the wells were washed four times with PBS, and the adherent cells were harvested and 
170 counted. Cell adhesion was determined staining cells with trypan blue and counting them under a 
171 phase-contrast microscope. All treatments were compared to the basal condition.
172
173 2.10. Statistical analysis
174 Statistical analysis was performed using GraphPad PRISM software V4.0 (GraphPad Software Inc, 
175 San Diego, California). Statistical comparisons among groups were carrying out by the Student t-
176 test or the one-way analysis of variance (ANOVA) followed by Tukey´s multiple comparison tests. 
177 Results were expressed as mean ± SEM. In all cases, only a p value < 0.05 was considered 
178 significant. 
179
180 3. Results 
181 3.1. Effect of EA on endometrial cell proliferation. 
182 The effects of both assayed concentrations of EA (50 and 100 µM) on cell proliferation are 
183 displayed in Figure 1. We did not find a statistically significant difference between EA and Basal, 
184 on cell proliferation in human endometrial epithelial (Figure 1A) or stromal (Figure 1B) cells. In the 
185 same way, we did not observe statistically significant effects of EA on ECC-1 (Figure 1C) and T-
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8186 HESCs (Figure 1D) cell proliferation. As shown in Figure 1, both cell lines and primary cultures 
187 behaved similarly, and facing the complexity conferred by the management and establishment of 
188 primary cultures 32; from this point we decided to continue using the ECC-1 and T-HESC cell lines 
189 as a representative in vitro experimental model. 
190
191 3.2. Effect of EA on endometrial cell cycle progression. 
192 The effects of both assayed concentration of EA (50 and 100 µM) on the progression of the cell 
193 cycle are displayed in Figure 2. Cell cycle distribution profiles of 24 and 48 h EA-treated cells were 
194 evaluated via flow cytometry. Only exposure to 100 µM EA for 48 h caused a significant arrest of 
195 cell cycle in G2/M phase in T-HESCs cells (Figure 2B; p<0.05); we have no observed significant 
196 differences with EA treatment in the other conditions in T-HESs or ECC-1 cells.
197  
198 3.3. Effect of EA on endometrial cell migration.
199 We evaluated the effects of EA on ECC-1 and T-HESCs cell migration by the wound healing 
200 technique (Figure 3). Treatment with 100 μM EA significantly decreased ECC-1 cell migration at 
201 20 h (Figure 3A; p<0.05) and T-HESC cell migration at 10 h and 20 h (Figure 3B; p<0.05 and 
202 p<0.001 respectively). In addition, 50 μM EA caused a significant decreased on T-HESC cell 
203 migration at 20 h (Figure 3B; p<0.01) even though no significant effects on ECC-1 cell migration 
204 was observed (Figure 3A). 
205  
206 3.4. Effect of EA on endometrial cell adhesion to plastic.  
207 We examined the adhesion of EA-treated ECC-1 and T-HESCs cells to plastic culture plates and 
208 compared this to attachment of untreated cells. As shown in Figure 4, the efficacy of EA-treated 
209 cells attachment was reduced on both cell lines. ECC-1 pre-treated with 50 and 100 µM EA 
210 significantly reduced their attachment competence (p<0.01 and p<0.001 vs. Basal respectively), and 
211 in the same way T-HESCs cells pre-treated showed a significant reduced attachment competence 
212 (p<0.05 and p<0.01 vs. Basal respectively). 
213
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9214  4. Discussion 
215 Endometriosis is one of the most common benign chronic hormonal woman diseases with poor 
216 prognosis and a high recurrence rate. Long-term therapy is required, and nowadays the current 
217 treatments are surgical and/or medical approaches. The pharmacological strategy is based on drugs 
218 that are generally ineffective because there is no balance between their clinical efficacy and the 
219 personal needs of patients 42. The choice between the treatments is influenced by several factors, 
220 including the type of lesion suspected, the personal insights of the patient, and the already known 
221 adverse effects that appear when hormonal drugs are used for a long period43. The variety of 
222 strategies and modalities demonstrates that treatment of endometriosis is constantly evolving and no 
223 single therapy is ideal for all patients. 
224 Over the last years, evidence has been accumulated to suggest that medicinal botanicals have 
225 anti-inflammatory and pain-alleviating properties and hold promise for treatment of 
226 endometriosis44. Taking into account previous results obtained in our laboratory45,46 and earlier 
227 promising results obtained in cancer15, we focus on possible natural therapies that prevent 
228 recurrences after laparoscopy. In this sense, EA is a polyphenol usually found in berries and nuts; 
229 and is one of the natural options that have lately been considered to treat different diseases. It 
230 affects a large range of biological activities and its mechanisms of action are varied.  At a systemic 
231 level, EA have shown to successfully inhibit angiogenesis, cell migration and cell invasion in 
232 ovarian, colon and bladder cancer cell lines15; some of the crucial processes for the infiltrative 
233 behavior and metastatic process as well as endometriosis patophisiology47,48. Accordingly to 
234 Sampson`s implantation theory2, endometriotic cells may migrate, attach, proliferate, and invade. 
235 These sequential cellular events are involved in the initiation, progression, and growth of ectopic 
236 endometriotic lesions, and therefore in the development of the disease.
237 In the present study, we analyze cell proliferation and cell cycle progression to assess the effect 
238 of EA on endometrial growth. Our data indicate that EA does not exert any effect nor in 
239 endometrial primary epithelial and stromal cells, neither on endometrial ECC-1 and T-HESC cell 
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240 lines (Figure 1). These results are in agreement with a previous work which demonstrates that EA in 
241 doses up to 50μM has no effect on cell proliferation in ECC-1 and T-HESCs cell lines49. However, 
242 it has been shown that 50 and 100µM EA suppresses the cell viability of U251 cells glioblastoma50.
243 In addition our cell cycle results showed that EA causes an arrest in the G2/M phase in T-HESCs 
244 after 48 h treatment (Figure 2). These results are congruent with González-Sarrías et al. 
245 investigation51 in which the exposure of Caco-2 cells to a mixture of EA and its metabolites (10 µM 
246 EA, 40 µM Urolithin A and 40 µM Urolithin B (Mix)) arrested cell growth at G2/M-phase since 
247 day 2 of treatment, associated to a downregulation of cyclins A and B1. On the other hand, we 
248 demonstrated that ECC-1 cell cycle progression is not affected by treatment with EA. This is 
249 consistent with previous works24, 52 in which it is demonstrated that EA has cell type-dependent 
250 effects on cell metabolism, suggesting that there is no a single target of action for this compound.
251  Interestingly, we observed that EA arrests cell cycle at G2/M-phase in T-HESCs cells but has no 
252 effect on cell proliferation. We think that this may be due to the fact that the arrest was observed at 
253 48h, the same time that cell proliferation was evaluated. Therefore it would be reasonable to find a 
254 decrease in cell proliferation at a later time, which was not analyzed in this work. In this regard, it 
255 has been reported that endometrial carcinoma KLE and AN3CA cell lines treated with EA 20µM 
256 for 24, 48 and 72 h, showed a significant decrease in cell viability only after 48 h53. However, 
257 during the same investigation, the arrest of the cell cycle in the G1 phase was evident at 24 h of 
258 treatment. Likewise, a study performed with apigenin, another natural compound, on pancreatic 
259 cancer cells54 detected a cell cycle arrest in the G2/M phase at 24 h of treatment, although the 
260 decrease in the number of cells was confirmed only at 72 h. 
261 Studies of the cellular mechanisms involved in the pathology of diseases are ideally carried out 
262 on primary cultured cells. However, the limited availability of tissue, the difficulties in establishing 
263 the culture, and the short useful life of these cells in subsequent passages leads to low 
264 reproducibility of assays32. Consequently, in this study we mainly use ECC-1 and T-HESCs cell 
Page 10 of 26Food & Function
Fo
od
&
Fu
nc
tio
n
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
22
 A
pr
il 
20
20
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f N
ew
 E
ng
la
nd
 o
n 
4/
22
/2
02
0 
2:
35
:4
2 
PM
. 
View Article Online
DOI: 10.1039/D0FO00267D
11
265 lines since they have been widely utilized as a model of endometriosis due to the close 
266 physiological55 and molecular32, 56-60 similarities they share with primary cultures.
267 As we mentioned before, cell migration and adhesion are key processes for the establishment of 
268 the lesions and the development of endometriosis1, 61, 62. Accordingly, we assessed the effect of EA 
269 on these cell abilities. We demonstrated that EA treatment reduces cell migration in both ECC-1 
270 and T-HESCs cells. In agreement with our results, Huidi Liu and col.63 demonstrates that the 
271 ovarian cancer cells (A2780) underwent inhibition of cell migration upon exposure to 5, 10 and 
272 15µg/ml EA. In addition, our results showed that pretreatment with EA decreases the ability of both 
273 cell lines to adhere to plastic (Figure 4). Congruently, a previous study conducted on neuroblastoma 
274 SH-SY5Y cells has already demonstrated that EA treatment (30µM) induces detachment and lower 
275 viability of adherent cells64.
276 It is know that many intracellular and soluble cellular adhesion molecules are differentially 
277 expressed in endometrial cells from women with and without endometriosis 65, 66 which may 
278 facilitate the implantation of endometrial cells in an ectopic place. Moreover, Zhao Q. and col.67 
279 demonstrated that endometrial stromal cells from ectopic endometrium have a higher rate of 
280 migration than stromal cells from normal endometrium. These reports highlight the importance of 
281 targeting cell migration and adhesion as they are central processes in endometriosis 
282 pathophysiology and support the use of EA as a putative compound for the treatment of this disease.
283 Nevertheless, EA is a polyphenolic compound from the family of ellagitannins, which have low 
284 water solubility and absorption leading to a poor bioavailability68, 69. This disadvantage could be a 
285 difficulty thinking it as a possible treatment for endometriosis. However, new promising approaches 
286 are being developed. Recently, poor water soluble drugs have been successfully delivered by the 
287 use of nanoscale systems70-72. Growing evidence demonstrates that this strategy allows the delivery 
288 of higher local concentrations of drugs, which can enhance their therapeutic efficacy73, 74. In this 
289 sense, novel drug-delivery systems that overcome the low EA solubility and bioavailability (i.e., 
290 biocompatible polymers-based nanoparticles/ microcapsules/ biofilms/ micelles) are being tested in 
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291 vitro and in vivo75-79. In summary, we found that EA affects cell cycle progression of endometrial 
292 stromal cells through the arrest at G2/M phase. Moreover, EA also inhibited the migration and 
293 adhesion of both stromal and epithelial cells suggesting that it could interfere with the early stages 
294 of lesion establishment. To the best of our knowledge our report constitutes the first study to test the 
295 effect of EA on endometriosis. Our results are promising even though more studies are needed to 
296 better understand the mechanisms of action of EA and it is the potential use as a preventive or 
297 therapeutic agent for endometriosis. Full characterization of this natural compound will likely 
298 provide new insights into alternative medicines with potential for therapeutic applications in 
299 women. In this context, further evaluation of the EA and its active metabolite(s) are currently being 
300 carry out by our group, in order to provide therapeutic alternatives for the inhibition of the 
301 development of endometriotic-type lesions.
302
303 Acknowledgements / Financial Support
304 This work was supported by grants from National Agency for Promotion of Science and 
305 Technology (ANPCYT) BID-PICT 2012-1056, CONICET PIP 1222015.  Fundación Instituto de 
306 Biología y Medicina Experimental, and Fundación René Barón.
307
308 Conflict of Interest
309 Authors declare no conflict of interest. NONE
310
311 Authorship
312 BMC, did all the experimental work and contributed new ideas. MAB taught and collaborated in the 
313 realization of the cell cultures, DM and AGR collaborated in the processing of the samples, JJS 
314 provided the endometrial tissue biopsies; RIB proposed the evaluation of the ellagic acid as a 
315 possible treatment for endometriosis, elaborated the work plan and direct the laboratory.
316
Page 12 of 26Food & Function
Fo
od
&
Fu
nc
tio
n
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
22
 A
pr
il 
20
20
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f N
ew
 E
ng
la
nd
 o
n 
4/
22
/2
02
0 
2:
35
:4
2 
PM
. 
View Article Online
DOI: 10.1039/D0FO00267D
13
317 5. References 
318 1. L.C. Giudice, L.C. Kao, Endometriosis, Lancet.,2004,364,1789.
319 2. J.A.Sampson, Peritoneal endometriosis due to menstrual dissemination of endometrial tissue 
320 into the peritoneal cavity, Am J Obs Gynecol., 1927,14,422. 
321 3. S. Kennedy, A. Bergqvist, C. Chapron, T. D’Hooghe, G. Dunselman, R. Greb, L. 
322 Hummelshoj, A. Prentice, E. Saridogan, ESHRE guideline for the diagnosis and treatment of 
323 endometriosis, Hum Reprod., 2005, 20,2698.
324 4. P. Vercellini, P. Viganò, E. Somigliana, L. Fedele, Endometriosis: pathogenesis and 
325 treatment, Nat Rev Endocrinol., 2014,10, 261.
326 5. S.W. Guo, Recurrence of endometriosis and its control, Hum Reprod Update., 2009, 15, 441.
327 6. G. Bozdag, Recurrence of endometriosis: risk factors, mechanisms and biomarkers, Womens 
328 Heal.(Lond), 2015,11, 693.
329 7. F. Barra, C. Scala, V. Mais, S. Guerriero, S. Ferrero, Investigational drugs for the treatment 
330 of endometriosis, an update on recent developments, Expert Opin Investig Drugs., 2018, 27, 
331 445.
332 8. A.K. Rodgers, T. Falcone, Treatment strategies for endometriosis, Expert Opin 
333 Pharmacother., 2008, 9, 243.
334 9. V. Selak, C. Farquhar, A. Prentice, A. Singla, Danazol for pelvic pain associated with 
335 endometriosis, Cochrane database Syst Rev., 2007, Issue 4, 1.
336 10. R.H. Liu, Potential Synergy of Phytochemicals in Cancer Prevention: Mechanism of Action, 
337 J Nutr, 2004, 134, 3479.
338 11. L. Wang, M. Martins-Green, Pomegranate and Its Components as Alternative Treatment for 
339 Prostate Cancer, Int J Mol Sci., 2014, 15, 14949.
340 12. R. Press, D. Hardcastle, Some physico-chemical properties of ellagic acid, J Appl Chem., 
341 2007, 19, 247.
342 13. J.M. Landete, Ellagitannins, ellagic acid and their derived metabolites: A review about 
343 source, metabolism, functions and health, Food Res., 2011, 44, 1150.
Page 13 of 26 Food & Function
Fo
od
&
Fu
nc
tio
n
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
22
 A
pr
il 
20
20
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f N
ew
 E
ng
la
nd
 o
n 
4/
22
/2
02
0 
2:
35
:4
2 
PM
. 
View Article Online
DOI: 10.1039/D0FO00267D
14
344 14. A.K. Kiss, J.P. Piwowarski, Ellagitannins, Gallotannins and their Metabolites- The 
345 Contribution to the Anti-Inflammatory Effect of Food Products and Medicinal Plants, Curr 
346 Med Chem., 2019, 25, 4946.
347 15. C. Ceci, P.M. Lacal, L. Tentori, M.G. De Martino, R. Miano, G. Graziani, Experimental 
348 Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid, 
349 Nutrients., 2018, 10, 1756. 
350 16. J.L. Ríos, R.M. Giner, M.C. Marín, M. Recio, A Pharmacological Update of Ellagic Acid, 
351 Planta Med., 2018, 84, 1068. 
352 17. I. Kang, T. Buckner, N.F. Shay, L. Gu, S. Chung, Improvements in Metabolic Health with 
353 Consumption of Ellagic Acid and Subsequent Conversion into Urolithins: Evidence and 
354 Mechanisms, Adv Nutr., 2016, 7, 961.
355 18. D. Gramec Skledar, T. Tomašič, M. Sollner Dolenc, L. Peterlin Mašič, A. Zega, Evaluation 
356 of endocrine activities of ellagic acid and urolithins using reporter gene assays, 
357 Chemosphere., 2019, 220, 706.
358 19. S.H. Park, J.L. Kim, E.S. Lee, S.Y. Han, J.H. Gong, M.K. Kang, Y.H. Kang, Dietary ellagic 
359 acid attenuates oxidized LDL uptake and stimulates cholesterol efflux in murine 
360 macrophages, J Nutr., 2011, 141, 1931.
361 20. L. Mele, P. Mena, A. Piemontese, V. Marino, N. López-Gutiérrez, F. Bernini, F. Brighenti, I. 
362 Zanotti, D. Del Rio, Antiatherogenic effects of ellagic acid and urolithins in vitro, Arch 
363 Biochem Biophys., 2016, 599, 42. 
364 21. K.N.M. Abdelazeem, Y. Singh, F. Lang, M.S. Salker, Negative Effect of Ellagic Acid on 
365 Cytosolic pH Regulation and Glycolytic Flux in Human Endometrial Cancer Cells, Cell 
366 Physiol Biochem., 2017, 41, 2374. 
367 22. P. Pitchakarn, T. Chewonarin, K. Ogawa, S. Suzuki, M. Asamoto, S. Takahashi, T. Shirai, P. 
368 Limtrakul, Ellagic Acid Inhibits Migration and Invasion by Prostate Cancer Cell Lines, Asian 
369 Pacific J Cancer Prev., 2013, 14, 2859.
370 23. J.N. Lossoa, R.R. Bansode, A. Trappey, H.A. Bawadi, R. Truax, In vitro anti-proliferative 
371 activities of ellagic acid, J Nutr Biochem., 2004, 15, 672. 
372 24. R. Vicinanza, Y. Zhang, S.M. Henning, D. Heber, Pomegranate Juice Metabolites, Ellagic 
Page 14 of 26Food & Function
Fo
od
&
Fu
nc
tio
n
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
22
 A
pr
il 
20
20
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f N
ew
 E
ng
la
nd
 o
n 
4/
22
/2
02
0 
2:
35
:4
2 
PM
. 
View Article Online
DOI: 10.1039/D0FO00267D
15
373 Acid and Urolithin A, Synergistically Inhibit Androgen-Independent Prostate Cancer Cell 
374 Growth via Distinct Effects on Cell Cycle Control and Apoptosis, Evidence-Based 
375 Complement Altern Med., 2013, 2013, 1.
376 25. L.S. Adams, Y. Zhang, N.P. Seeram, D. Heber, S. Chen, Pomegranate ellagitannin-derived 
377 compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro, 
378 Cancer Prev Res., 2010, 3, 108. 
379 26. H.S. Aiyer, R.C. Gupta, Berries and ellagic acid prevent estrogen-induced mammary 
380 tumorigenesis by modulating enzymes of estrogen metabolism, Cancer Prev Res., 2010, 3, 
381 727. 
382 27. K.P.L. Bhat, J.M. Pezzuto, Natural modulators of estrogen biosynthesis and function as 
383 chemopreventive agents, Arch Pharm Res., 2001, 24, 473. 
384 28. ASRM. Revised American Society for Reproductive Medicine classification of 
385 endometriosis: 1996, Fertil Steril., 1997, 67, 817.
386 29. G.F. Meresman, S. Vighi, R.A. Buquet, O. Contreras-Ortiz, M. Tesone, L.S. Rumi, 
387 Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with 
388 endometriosis, Fertil Steril., 2000, 74, 760. 
389 30. H. Cho, H. Jung, H. Lee, H.C. Yi, H.K. Kwak, K.T. Hwang, Correction: Chemopreventive 
390 activity of ellagitannins and their derivatives from black raspberry seeds on HT-29 colon 
391 cancer cells, Food Funct., 2015, 6, 2861.
392 31. G.F. Meresman, M. Bilotas, R.A. Buquet, R.I. Barañao, C. Sueldo, M. Tesone, 
393 Gonadotropin-releasing hormone agonist induces apoptosis and reduces cell proliferation in 
394 eutopic endometrial cultures from women with endometriosis, Fertil Steril., 2003, 80, 702.
395 32. G. Krikun, G. Mor, A. Alvero, S. Guller, F. Schatz, E. Sapi, M. Rahman, R. Caze, M. 
396 Qumsiyeh, CJ. Lockwood, A Novel Immortalized Human Endometrial Stromal Cell Line 
397 with Normal Progestational Response, Endocrinology., 2004, 145, 2291. 
398 33. P.G. Satyaswaroop, R.J. Zaino, R. Mortel, Human endometrial adenocarcinoma transplanted 
399 into nude mice: growth regulation by estradiol, Science., 1983, 219, 58.
400 34. K.L. Khanduja, P.K. Avti, S. Kumar, N. Mittal, K.K. Sohi, C.M. Pathak, Anti-apoptotic 
401 activity of caffeic acid, ellagic acid and ferulic acid in normal human peripheral blood 
Page 15 of 26 Food & Function
Fo
od
&
Fu
nc
tio
n
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
22
 A
pr
il 
20
20
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f N
ew
 E
ng
la
nd
 o
n 
4/
22
/2
02
0 
2:
35
:4
2 
PM
. 
View Article Online
DOI: 10.1039/D0FO00267D
16
402 mononuclear cells: a Bcl-2 independent mechanism, Biochim Biophys Acta., 2006, 1760, 
403 283. 
404 35. A.R. Sudheer, S. Muthukumaran, N. Devipriya, V.P. Menon, Ellagic acid, a natural 
405 polyphenol protects rat peripheral blood lymphocytes against nicotine-induced cellular and 
406 DNA damage in vitro: With the comparison of N-acetylcysteine, Toxicology., 2007, 230, 11.
407 36. D. Wang, Q. Chen, Y. Tan, B. Liu, C. Liu, Ellagic acid inhibits human glioblastoma growth 
408 in vitro and in vivo, Oncol Rep., 2017, 37, 1084.
409 37. L. Vanella, C. Di Giacomo, R. Acquaviva, I. Barbagallo, G. Li Volti, V. Cardile, N.G. 
410 Abraham, V. Sorrenti, Effects of ellagic Acid on angiogenic factors in prostate cancer cells, 
411 Cancers., 2013, 5, 726.
412 38. A. Promsong, W.O. Chung, S. Satthakarn, W. Nittayananta, Ellagic acid modulates the 
413 expression of oral innate immune mediators: potential role in mucosal protection, J Oral 
414 Pathol Med., 2015, 44, 214. 
415 39. A. Strati, Z. Papoutsi, E. Lianidou, P. Moutsatsou, Effect of ellagic acid on the expression of 
416 human telomerase reverse transcriptase (hTERT) alpha+beta+ transcript in estrogen receptor-
417 positive MCF-7 breast cancer cells, Clin Biochem., 2009, 42, 1358.
418 40. C.C. Liang, A.Y. Park, J.L. Guan, In vitro scratch assay: a convenient and inexpensive 
419 method for analysis of cell migration in vitro, Nat Protoc., 2007, 2, 329.
420 41. Y. Chen, W. Peng, Y. Lu, J. Chen, Y.Y. Zhu, T. Xi, MiR-200a enhances the migrations of 
421 A549 and SK-MES-1 cells by regulating the expression of TSPAN1, J Biosci., 2013, 38, 
422 523. 
423 42. S. Ferrero, G. Evangelisti, F. Barra, Current and emerging treatment options for 
424 endometriosis, Expert Opin Pharmacother., 2018, 19, 1109.
425 43. A.M. Quaas, E.A. Weedin, K.R. Hansen, On-label and off-label drug use in the treatment of 
426 endometriosis, Fertil Steril, 2015, 103, 612. 
427 44. F. Wieser, M. Cohen, A. Gaeddert, J. Yu, C. Burks-Wicks, S.L. Berga, R.N. Taylor, 
428 Evolution of medical treatment for endometriosis: back to the roots?, Hum Reprod Update., 
429 2007, 13, 487.
430 45. A.G. Ricci, C.N. Olivares, M.A. Bilotas, J.I. Bastón, J.J. Singla, G.F. Meresman, R.I. 
Page 16 of 26Food & Function
Fo
od
&
Fu
nc
tio
n
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
22
 A
pr
il 
20
20
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f N
ew
 E
ng
la
nd
 o
n 
4/
22
/2
02
0 
2:
35
:4
2 
PM
. 
View Article Online
DOI: 10.1039/D0FO00267D
17
431 Barañao, Natural therapies assessment for the treatment of endometriosis, Hum Reprod., 
432 2013, 28, 178.
433 46. L. Ferella, J.I. Bastón, M.A. Bilotas, J.J. Singla, A.M. González, C.N. Olivares, G.F. 
434 Meresman, Active compounds present in Rosmarinus officinalis leaves and Scutellaria 
435 baicalensis root evaluated as new therapeutic agents for endometriosis, Reprod Biomed 
436 Online., 2018, 37, 769.
437 47. M.D. Spuijbroek, G.A. Dunselman, P.P. Menheere, J.L. Evers, Early endometriosis invades 
438 the extracellular matrix, Fertil Steril., 1992, 58, 929.
439 48. C.A. Witz, S. Cho, V.E. Centonze, I.A. Montoya-Rodriguez, R.S. Schenken, Time series 
440 analysis of transmesothelial invasion by endometrial stromal and epithelial cells using three-
441 dimensional confocal microscopy, Fertil Steril., 2003, 79, 770.
442 49. W. Zhang, J.H. Chen, I. Aguilera-Barrantes, C.W. Shiau, X. Sheng, L.S. Wang, G.D. Stoner, 
443 Y.W. Huang, Urolithin A suppresses the proliferation of endometrial cancer cells by 
444 mediating estrogen receptor-α-dependent gene expression, Mol Nutr Food Res., 2016, 60, 
445 2387.
446 50. D. Wang, Q. Chen, B. Liu, Y. Li, Y. Tan, B. Yang, Ellagic acid inhibits proliferation and 
447 induces apoptosis in human glioblastoma cells, Acta Cir Bras., 2016, 31, 143.
448 51. A. González-Sarrías, J.C. Espín, F.A. Tomás-Barberán, M.T. García-Conesa, Gene 
449 expression, cell cycle arrest and MAPK signalling regulation in Caco-2 cells exposed to 
450 ellagic acid and its metabolites, urolithins,  Mol Nutr Food Res., 2009, 53, 686.
451 52. A.L. Boehning, S.A. Essien, E.L. Underwood, P.K. Dash, D. Boehning, Cell type-dependent 
452 effects of ellagic acid on cellular metabolism, Biomed Pharmacother., 2018, 106, 411.
453 53. Y. Wang, F. Ren, B. Li, Z. Song, P. Chen, L. Ouyang, Ellagic acid exerts antitumor effects 
454 via the PI3K signaling pathway in endometrial cancer, J Cancer., 2019, 10, 3303.
455 54. M.B. Ujiki, X.Z. Ding, M.R. Salabat, D.J. Bentrem, L. Golkar, B. Milam, M.S. Talamonti, 
456 R.H. Jr. Bell, T. Iwamura, T.E. Adrian, Apigenin inhibits pancreatic cancer cell proliferation 
457 through G2/M cell cycle arrest, Mol Cancer., 2006, 5, 76.
458 55. R.J. Zhang, R.A. Wild, D. Medders, S.R. Gunupudi, Effects of peritoneal macrophages from 
459 patients with endometriosis on the proliferation of endometrial carcinoma cell line ECC-1, 
Page 17 of 26 Food & Function
Fo
od
&
Fu
nc
tio
n
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
22
 A
pr
il 
20
20
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f N
ew
 E
ng
la
nd
 o
n 
4/
22
/2
02
0 
2:
35
:4
2 
PM
. 
View Article Online
DOI: 10.1039/D0FO00267D
18
460 Am J Obstet Gynecol., 1991, 165(6 Pt 1), 1842. 
461 56.  R. Zhang, R.A. Wild, D. Medders, S.R. Gunupudi, Effects of peritoneal macrophages from 
462 patients with endometriosis on the proliferation of endometrial carcinoma cell line ECC-l, 
463 Am J Obstet Gynecol., 1991, 165, 1842.
464 57. B. Mo, A.E. Vendrov, W.A. Palomino, B.R. DuPont, K.B.C. Apparao, B.A. Lessey, ECC-1 
465 Cells: A Well-Differentiated Steroid-Responsive Endometrial Cell Line with Characteristics 
466 of Luminal Epithelium, Biology of Reproduction., 2006, 75, 387.
467 58. S.S. Tabibzadeh, P.G. Statyaswaroop, P.N. Rao, Antiproliferative Effect of Interferon-7 in 
468 Human Endometrial Epithelial Cells in Vitro: Potential Local Growth Modulatory Role in 
469 Endometrium, Journal of Clinical Endocrinology and Metabolism., 1988, 67, 131.
470 59. M. Annunziata, C. Grande, F. Scarlatti, F. Deltetto, E. Delpiano, M. Camanni, E. Ghigo, R. 
471 Granata, The growth hormone-releasing hormone (GHRH) antagonist JV-1-36 inhibits 
472 proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T 
473 HESC cell line, Fertil Steril., 2010, 94(3), 841.
474 60. X. Wen, Y. Xiong, L. Jin, M. Zhang, L. Huang, Y. Mao, C. Zhou, Y. Qiao, Y. Zhang, 
475 Bisphenol A Exposure Enhances Endometrial Stromal Cell Invasion and Has a Positive 
476 Association with Peritoneal Endometriosis, Reproductive Sciences., 2019, 27, 704.
477 61. P.A. Klemmt, J.G. Carver, P. Koninckx, E.J. McVeigh, H.J. Mardon, Endometrial cells from 
478 women with endometriosis have increased adhesion and proliferative capacity in response to 
479 extracellular matrix components: towards a mechanistic model for endometriosis 
480 progression, Hum Reprod., 2007, 22, 3139.
481 62. C.A. Witz, M.R. Thomas, I.A. Montoya-Rodriguez, A.S. Nair, V.E. Centonze, R.S. 
482 Schenken, Short-term culture of peritoneum explants confirms attachment of endometrium to 
483 intact peritoneal mesothelium, Fertil Steril. 2001, 75, 385.
484 63. H. Liu, Z. Zeng, S. Wang, T. Li, E. Mastriani, Q.H. Li, H.X. Bao, Y.J. Zhou, X. Wang, Y. 
485 Liu, W. Liu, S. Hu, S. Gao, M. Yu, Y. Qi, Z. Shen, H. Wang, T. Gao, L. Dong, R.N. 
486 Johnston, S.L. Liu, Main components of pomegranate, ellagic acid and luteolin, inhibit 
487 metastasis of ovarian cancer by down-regulating MMP2 and MMP9, Cancer Biol Ther., 
488 2017, 18, 990.
489 64. C. Fjaeraa, E. Nånberg, Effect of ellagic acid on proliferation, cell adhesion and apoptosis in 
Page 18 of 26Food & Function
Fo
od
&
Fu
nc
tio
n
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
22
 A
pr
il 
20
20
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f N
ew
 E
ng
la
nd
 o
n 
4/
22
/2
02
0 
2:
35
:4
2 
PM
. 
View Article Online
DOI: 10.1039/D0FO00267D
19
490 SH-SY5Y human neuroblastoma cells, Biomed Pharmacother., 2009, 63, 254.
491 65. B.A. Lessey, A.J. Castelbaum, S.W. Sawin, C.A. Buck, R. Schinnar, W. Bilker, B.L. Strom, 
492 Aberrant integrin expression in the endometrium of women with endometriosis, J Clin 
493 Endocrinol Metab., 1994, 79, 643.
494 66. C.M. Kyama, L. Overbergh, A. Mihalyi, C. Meuleman, J.M. Mwenda, C. Mathieu, T.M. 
495 D'Hooghe, Endometrial and peritoneal expression of aromatase, cytokines, and adhesion 
496 factors in women with endometriosis, Fertil Steril., 2008, 89, 301.
497 67. Q. Zhao, M. Ye, W. Yang, M. Wang, M. Li, C. Gu, L. Zhao, Z. Zhang, W. Han, W. Fan, Y. 
498 Meng, Effect of Mst1 on Endometriosis Apoptosis and Migration: Role of Drp1-Related 
499 Mitochondrial Fission and Parkin-Required Mitophagy. Cell Physiol Biochem, 2018, 45, 
500 1172.
501 68. A. González-Sarrías, R. García-Villalba, M.A. Núñez-Sánchez, J. Tomé-Carneiro, P. Zafrilla, 
502 J. Mulero, F.A. Tomás-Barberán, J.C. Espín, Identifying the limits for ellagic acid 
503 bioavailability: A crossover pharmacokinetic study in healthy volunteers after consumption 
504 of pomegranate extracts, J Funct Foods., 2015, 19, 225.
505 69. J. Long, Y. Guo, J. Yang, S.M. Henning, R.P. Lee, A. Rasmussen, L. Zhang, Q.Y. Lu, D. 
506 Heber, Z. Li Z,Bioavailability and bioactivity of free ellagic acid compared to pomegranate 
507 juice, Food Funct, 2019, 10, 6582.
508 70. Z. Aytac, S. I. Kusku, E. Durgun, T. Uyar, Encapsulation of Gallic Acid/cyclodextrin 
509 Inclusion Complex in Electrospun Polylactic Acid Nanofibers: Release Behavior and 
510 Antioxidant Activity of Gallic Acid, Mater. Sci. Eng. C., 2016, 63, 231.
511 71. H. Wang, Y. Zhang, Zh. Tian, J. Ma, M. Kang, Ch. Ding, D. Ming, Preparation of β-CD-
512 Ellagic Acid Microspheres and Their Effects on HepG2 Cell Proliferation, Molecules., 2017, 
513 22, 2175.
514 72. Ch-Y. Qu, Min Zhou, Y-w. Chen, M-m. Chen, F. Shen, l-M. Xu, Engineering of Lipid 
515 Prodrug-Based, Hyaluronic Acid-Decorated Nanostructured Lipid Carriers Platform for 5-
516 Fluorouracil and Cisplatin Combination Gastric Cancer Therapy, Int J Nanomedicine., 2015, 
517 10, 3911.
518 73. N. Fomina, J. Sankaranarayanan, A. Almutairi, Photochemical Mechanisms of 
519 LightTriggered Release from Nanocarriers, Adv. Drug Deliv. Rev., 2012, 64, 1005.
Page 19 of 26 Food & Function
Fo
od
&
Fu
nc
tio
n
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
22
 A
pr
il 
20
20
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f N
ew
 E
ng
la
nd
 o
n 
4/
22
/2
02
0 
2:
35
:4
2 
PM
. 
View Article Online
DOI: 10.1039/D0FO00267D
20
520 74. W. Wu, W. Yao, X. Wang, C. Xie, J. Zhang, X. Jiang, Bioreducible heparin-based nanogel 
521 drug delivery system, Biomaterials, 2015, 39, 260.
522 75. Y. Jeong, R.P. Yv, T. Ohno, Y. Yoshikawa, N. Shibata, S. Kato, K. Takeuchi and K. Takada, 
523 Application of Eudragit P-4135F for the delivery of ellagic acid to the rat lower small 
524 intestine, J Pharma Pharmacol., 2001, 53, 1079
525 76. A.M. Avachat, V.G. Patel, Self-nanoemulsifying drug delivery system of stabilized ellagic 
526 acid–phospholipid complex with improved dissolution and permeability, Saudi Pharm J., 
527 2015, 23, 276
528 77. C. Ding, H. Bi, D. Wang, M. Kang, Z. Tian, Y. Zhang, H. Wang, T. Zhu, and J. Ma, 
529 Preparation of Chitosan/Alginate-ellagic Acid Sustained-release Microspheres and their 
530 Inhibition of Preadipocyte Adipogenic Differentiation, Curr Pharm Biotechnol, 2019, 20, 
531 1213.
532 78. K. Sonaje, J. L. Italia, G. Sharma, V. Bhardwaj, K. Tikoo, M. N. Kumar, Development of 
533 Biodegradable Nanoparticles for Oral Delivery of Ellagic Acid and Evaluation of Their 
534 Antioxidant Efficacy against Cyclosporine A-Induced Nephrotoxicity in Rats, Pharm Res., 
535 2007, 24, 899
536 79. O.M. Ali, A.A. Bekhit, S.N. Khattab, M.W. Helmy, Y.S. Abdel-Ghany, M. Teleb, A.O. 
537 Elzoghby, Synthesis of Lactoferrin Mesoporous Silica Nanoparticles for Pemetrexed/Ellagic 
538 Acid Synergistic Breast Cancer Therapy, Colloids Surf B Biointerfaces, 2020, 188, 110824.
539
Page 20 of 26Food & Function
Fo
od
&
Fu
nc
tio
n
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
22
 A
pr
il 
20
20
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f N
ew
 E
ng
la
nd
 o
n 
4/
22
/2
02
0 
2:
35
:4
2 
PM
. 
View Article Online
DOI: 10.1039/D0FO00267D
21
540 Figure captions 
541 Figure 1: Effects of EA on cell proliferation in epithelial (A) and stromal (B) primary cell cultures 
542 from patients with Endometriosis and controls; and in ECC-1 (C) and T-HESCs (D) cells. Cell 
543 cultures were treated with EA 50 and 100 µM or vehicle (Basal group) for 24 or 48 h and cell 
544 proliferation was assessed by WST assay. N is expressed between parentheses in each bar.
545
546 Figure 2: Effect of EA on cell cycle distribution in ECC-1 (A) and T-HESCs (B) cells. Cell 
547 cultures were treated with EA 50 and 100 µM or vehicle (Basal group) for 24 or 48 h. Cell cycle 
548 was assessed by staining DNA with propidium iodide and analyzed with flow cytometer. 
549 Fluorescence-activated cell sorting (FACS) analysis of the cell cycle distribution for the Basal 
550 condition and for 50 and 100µM EA treatment for 24 h (i) and 48 h (iii). Comparison of percentage 
551 of cells in each stage of the cell cycle after EA treatment for 24 h (ii) and 48 h (iv). N=5. *P < 0.05 
552 versus Basal.
553
554 Figure 3: Effect of EA on cell migration in ECC-1 (A) and T-HESCs (B) cells. Cell cultures were 
555 treated with EA 50 and 100 µM or vehicle (Basal group) and images were captured at 0, 5, 10 and 
556 20 h after scratch. Quantitative analysis of the open wound was performed using Image J software 
557 and expressed as the percentage of 0 h wound for each treatment. Each point represents the mean of 
558 five experiments, performed in duplicate. *P < 0.05 and ***P < 0.001 100 µM EA versus Basal; ## 
559 P < 0.01 50 µM EA versus Basal.
560
561 Figure 4: Effect of EA on ECC-1 (A) and T-HESCs (B) cell attachment to plastic. Cell cultures 
562 were treated with EA 50 and 100 µM or vehicle (Basal group). After 24 h cells were harvested and 
563 let them to adhere to plastic for 1 h, and the number of attached cells was counted under a 
564 microscope. **P < 0.01 and ***P < 0.001 versus Basal. N is expressed between parentheses in each 
565 bar.
566
567 Table1: Characteristics of biopsies.
568
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569 Figures
570 Figure 1:
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578 Figure 3:
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581 Figure 4:
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584 Tables
585 Table1: 
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progression of endometrial stromal cell line cycle.
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